President Donald Trump’s proposed budget includes a “user fee” for e-cigarettes. The fee, which could add $100 million to federal coffers, would fund FDA oversight of e-cigarettes and other new types of tobacco products. (Reuters)

At-home DNA-testing company 23andMe has rolled out a report that will assess a user’s risk of developing type 2 diabetes. The company tested 2.5 million users who opted-in to participate in research on their likelihood of developing the most common form of diabetes. (CNBC)

Republicans are seeing a 2020 talking point developing in Democrats’ calls for a “Medicare for All” system. Republican pollsters and strategists are reportedly planning to associate Democrats running for Congress and other posts with “socialized medicine” in the next election cycle. (Associated Press)

The FDA has approved the expanded use of an eczema drug from Regeneron and Sanofi to include patients between 12 and 17 years old. Dupixent was first approved in 2017. It has been used as a treatment for adults with atopic dermatitis, as well as some with asthma. (Reuters)

Principia and AbbVie are walking away from a partnership inked two years ago to develop inflammatory and autoimmune drugs. Principia’s leader said on Monday that AbbVie had decided the deal was no longer a strategic fit. (Endpoints)